Manlio Bolla

🎯 What if viruses became our greatest allies against cancer?   Oncolytic viruses are among the most promising advances in oncological immunotherapy. Able to selectively target and destroy tumor cells while stimulating the immune response, they are opening a new era in the fight against cancer.   But turning a promising candidate into a clinical drug is no easy feat from from early research to GMP manufacturing batches meeting regulatory requirements.   That's exactly where Naobios comes in.    And to walk you through it, we've sent our best experts to the front line: 🙋 Benjamin, our Business Development Manager, who knows the journey of your projects better than anyone.  🦠 Oliv, our oncolytic virus mascot, who… well, knows exactly what we're talking about. From the inside.   Together, they guide you through every step:  ✅ Bioprocess development and optimization  ✅ Preclinical batch production  ✅ GMP manufacturing of clinical batches (grade A/B GMP workshop, GMP Annex I compliant) ✅ Quality control in collaboration with our sister company Clean Cells   🎬 Ready to watch a Business Dev and an oncolytic virus team up? Check out the video below 👇😄   #OncolyticViruses #CDMO #GMP #Immunotherapy

25

Extending TAP-targeted neoantigen induction beyond oncology Sebastian BioPharma is proud to announce the publication of our new study in The Journal of Infectious Diseases  https://lnkd.in/eQgKmKee, demonstrating that our iTAP neoantigen-induction concept—originally developed to enhance tumor immunity—also applies to infectious diseases. We show that HIV-, CMV-, and EBV-infected cells with reduced TAP expression—whether naturally occurring or experimentally induced using our antibody-oligonucleotide conjugate platform—present the same cryptic neoantigens previously identified in TAP-low tumor cells. CD8⁺ T cells stimulated against these antigens effectively recognize and eliminate the infected cells. This work highlights that the iTAP concept enables a unified immune response spanning oncology and infectious disease, bypassing pathogen-specific antigen discovery and overcoming antigenic heterogeneity. Our antibody-oligonucleotide conjugate platform, now used to implement iTAP in vivo, demonstrates how precise manipulation of TAP expression can form the basis of a broadly applicable therapeutic strategy capable of targeting most tumors or pathogen-infected cells in which TAP is downregulated. More to come as we continue advancing this transformative concept.

11

1 commentaire

Seeing Cancer in Its DNA: The Origins of Precision Medicine Today, molecular profiling of tumours is considered an essential part of modern oncology and one of the foundations of precision medicine. But this approach was once a radical idea. Back in 2011, three physician-researchers at Gustave Roussy - Professor Fabrice André, Dr Suzette Delaloge and Professor Jean-Charles Soria—published a landmark article proposing a new way of thinking about cancer treatment: rather than looking at just one or two genetic markers, why not examine the tumour more comprehensively to identify the molecular changes that could be targeted with specific treatments? At the time, targeted therapies were showing enormous promise, but clinicians faced a major challenge. New genetic mutations were being discovered all the time, while existing technologies could often examine only one gene at a time. The question was becoming increasingly important: how do we identify the right treatment for the right patient as quickly as possible? The answer was to look more deeply into the biology of each individual tumour. This vision soon began to translate into clinical practice. In 2010, Gustave Roussy established its first multidisciplinary molecular tumour board for patients with metastatic lung cancer. This brought specialists together to examine patients' tumour profiles and determine whether specific mutations could be targeted through an available treatment or clinical trial. Then came pioneering research programmes such as SAFIR01 and MOSCATO, which explored whether large-scale molecular profiling could realistically be used to guide treatment decisions. The results helped demonstrate that it was possible to analyse tumours at this scale within clinically relevant timeframes and, for some patients, identify treatment options that could improve outcomes. Professor Fabrice André recalls those early molecular tumour boards as a defining moment in his career: “We felt we were paving the way for an approach that we already sensed would become a lasting feature of oncology.” And they were. Fifteen years on, molecular profiling has become an increasingly important part of cancer care. Rather than treating cancers solely according to where they originated in the body, researchers are increasingly able to consider what is happening inside the tumour itself—its genes, cells and biological characteristics. The journey hasn't ended. Today's research is moving beyond genomics to explore the complexity of tumours at the cellular and molecular level, with the ultimate ambition of understanding each cancer as precisely as possible and using that knowledge to tailor treatment to the individual patient. What began as a pioneering vision in 2011 is helping to shape the medicine of tomorrow. #CancerResearch #PrecisionMedicine #Oncology #CancerCare #MolecularProfiling #GustaveRoussy #CancerInnovation #medicalresearch Credit: https://lnkd.in/gAzRPih

2

1 commentaire